DP056 | PHASE III COMMODORE-1 TRIAL: 2-YEAR EFFICACY AND SAFETY OF CROVALIMAB IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA WHO SWITCHED FROM RAVULIZUMAB

Crovalimab (crova) is a novel C5 inhibitor (C5i) allowing for maintenance subcutaneous (SC) injection every 4 wks (Q4W). COMMODORE 1 study demonstrated the safety and exploratory efficacy of crova in randomized pts who switched from eculizumab (ecu); this study also had a non-randomized arm with pt...

Full description

Bibliographic Details

Published in:	Haematologica
Main Authors:	B. Fattizzo, P. Scheinberg, H. Alzahrani, A. Contento Gonzalo, M. Höglund, J. S. Kim, J. Panse, M. J. Rose, J. Schubert, Y. Ueda, E. S. Yap, M. Buri, N. Compagno, B. Gentile, S. Sreckovic, A. G. Kulasekararaj
Format:	Article
Language:	English
Published:	Ferrata Storti Foundation 2025-09-01
Online Access:	https://haematologica.org/article/view/12698